VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
Status:
RECRUITING
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
Venous thromboembolism (VTE) has a high prevalence in patients with multiple comorbidities undergoing complex surgical procedures. Sometimes, extended prophylaxis for VTE with KLMWH or direct oral anticoagulants (DOACs) is necessary. Currently, there is no consensus in the literature regarding the use of DOACs for extended VTE prophylaxis in patients undergoing lower limb revascularization (LLR). Objective: To evaluate the use of DOACs (already approved to reduce MACE and MALE) in VTE prophylaxis in patients undergoing LLR.
Phase:
PHASE4
Details
Lead Sponsor:
Science Valley Research Institute
Treatments:
Aspirin BID protein, human Clopidogrel Endovascular Procedures Rivaroxaban